Compare

Jyong Biotech Ltd. vs Nexentis Technologies Inc. vs Emmaus Life Sciences, Inc. vs Phio Pharmaceuticals Corp.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearJyong Biotech Ltd.
MENS
Nexentis Technologies Inc.
NXTS
Emmaus Life Sciences, Inc.
EMMA
Phio Pharmaceuticals Corp.
PHIO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/an/a$12.45Mn/a
Revenue growth (YoY)n/an/a-25.2%n/a
Gross marginn/an/a93.1%n/a
Operating marginn/an/a1.9%n/a
Net marginn/an/a-60.2%n/a
Net income-$4.67M-$4.00M-$7.49M-$8.70M
EPS (Diluted)-$0.06-$8.61-$0.12n/a
Operating cash flow-$3.04M-$3.81M-$11.0K-$7.98M
Free cash flown/a-$3.82M-$12.0K-$7.99M
Cash & equivalentsn/a$3.83M$2.13M$21.03M
Total assets$20.78M$20.41M$21.44M$21.49M
Total liabilities$45.68M$4.67M$85.04M$1.34M
Shareholders' equity-$24.91M$16.01M-$63.61M$20.15M
Return on year-end equityn/a-25.0%n/a-43.2%
Shares outstanding76.03M2.77M70.19M11.62M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearJyong Biotech Ltd.Nexentis Technologies Inc.Emmaus Life Sciences, Inc.Phio Pharmaceuticals Corp.
Latestn/a$210.0K
Ended 2024-12-31
$12.45M
Ended 2025-12-31
$0
Ended 2020-12-31
1 year earliern/a$263.0K
Ended 2023-12-31
$16.65M
Ended 2024-12-31
$21.0K
Ended 2019-12-31
2 years earliern/a$394.0K
Ended 2022-12-31
$29.60M
Ended 2023-12-31
$138.0K
Ended 2018-12-31
3 years earliern/a$438.1K
Ended 2021-12-31
$18.39M
Ended 2022-12-31
$15.0K
Ended 2017-12-31
4 years earliern/a$232.3K
Ended 2020-12-31
$20.61M
Ended 2021-12-31
$19.0K
Ended 2016-12-31